Comment on: A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis SIR, We were interested to read the recent paper by Derk et al. [1] describing an open-label study of mycophenolate mofetil (MMF) in dcSSc. Of 15 patients, 12 completed at least 3 months of therapy, and in these 12 patients mean modified Rodnan skin score fell from 22.5 at study entry to 8.4 after 12 months.
Although these results are encouraging, and we share the authors' belief that MMF deserves further study as a possible disease-modifying therapy for early dcSSc, a note of caution is required. This is because although dcSSc is associated with high morbidity and mortality, a proportion of patients demonstrate spontaneous improvement in skin score. Related to this, several treatments that have appeared promising in initial studies have not stood the test of randomized controlled clinical trials: examples include a-IFN [2, 3] and relaxin [4, 5] .
In the recently reported UK observational study of 147 patients with early dcSSc [6] , we reported treatment outcome in 61 patients treated with MMF. Overall, the outcome in MMF-treated cases was not significantly different (in terms of rate of skin score change) from other treatment groups (including cyclophosphamide, antithymocyte globulin followed by MMF, or no diseasemodifying treatment). In 35 patients treated with MMF with skin score data at 1 year, the mean change in skin score was À4.3 (95% CI À7.3, À1.3). The observational approach has specific limitations, including difficulties in interpretation due to some patients changing protocol, which in the UK study precluded firm conclusions regarding whether or not immunosuppression conferred benefit [6] . However, our study [6] does confirm the feasibility of long-term prospective cohort studies in dcSSc. Randomized controlled clinical trials are very difficult to mount in early dcSSc. We are delighted that the European League Against Rheumatism (EULAR), via its Orphan Disease Programme, is funding a large-scale European observational study of treatment outcome in early dcSSc. In this study, which will commence later this year, entry and outcome data will be captured in a standardized way, and patient baseline and follow-up differences in treatment allocation will be adjusted for using modern statistical methods. The pragmatic approach of 'real-life' observational studies allows much larger numbers of patients to be studied than in controlled clinical trials.
One of the treatment protocols in the EULAR-funded study will be MMF and so we are optimistic that in www.rheumatology.oxfordjournals.org 4 years' time we shall be in a much stronger position to
